

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
200.1079US

SERIAL NO.: 09/154,334

10/033,055

## LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Ronald M. BURCH, et al.

FILING DATE:  
September 17, 1998

GROUP: 1614

1639

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
MA	AA	5 8 5 9 2 5 7	01/12/9	Talley	548	247	08/14/96
	AB	5 8 6 3 9 2 2	01/26/99	Mayer, et al.	514	270	07/02/99
	AC	5 8 4 0 7 3 1	11/24/98	Mayer, et al.	514	289	08/02/95
	AD	5 8 6 9 4 9 8	02/09/99	Mayer, et al.	514	282	07/07/97
	AE	5 8 6 1 4 1 9	01/19/99	Dube, et al.	514	334	07/11/97
	AF	5 7 8 9 4 1 3	08/04/98	Black, et al.	514	255	01/21/97
	AG	5 6 0 4 2 6 0	02/18/97	Guay, et al.	514	605	11/04/93
	AH	5 4 5 8 8 7 9	10/17/95	Singh, et al.	424	400	09/30/94
	AI	5 5 1 6 8 0 3	05/14/96	Raffa	514	570	03/01/95
M	AJ	5 8 4 3 4 6 8	12/01/98	Burkoth, et al.	424	448	05/13/96
	AK						

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

MA	AL	Differential Inhibition of Cyclooxygenase-1 (COX-1) and -2 (COX) By NSAIDS: Consequences on Anti-Inflammatory Activity Versus Gastric and Renal Safety, M. Palret, et al., Inflammopharmacology 4: 61-70, (1996).
	AM	Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation, Derek W. Gilroy, et al. European J. Pharm 355 pp 211-217, (1998).
	AN	Cyclooxygenases 1 and 2, J.R. Vane, et al. Annu. Rev. Pharmacol. Toxicol. 38: 97-121, (1998).
	AO	Analysis of the effects of cyclooxygenase (COX)-1 and COX-2 in spinal nociceptive transmission using indomethacin, a non-selective COX inhibitor, and NS-398, a COX-2 selective inhibitor, Tatsuo Yamamoto, et al. Brain Research 739:104-110, (1996).
	AP	Comparative Analgesic Efficacy of Nimesulide and Diclofenac Gels after Topical Application on the Skin, S. Sengupta, et al., Skin Pharmacol. And Applied Skin Phys. 11: 273-278, (1998).
	AQ	Carrageenan-induced hyperalgesia is associated with increased cyclo-oxygenase-2 expression in spinal cord, Cariona Hay and Jacqueline de Belleruche, NeuroReport 8, 1249-1251, (1997).
	AR	The Mechanisms of Action of NSAIDs in Analgesia, Jeremy N. Cashman, Drugs 52 Supp. 5:13-23, (1996).
	AS	Differential effects of inhibition of isoforms of cyclooxygenase (COX-1, COX-2) in chronic inflammation, D.W. Gilroy, et al. Inflamm. Res. 47: 79-85, (1998).
M	AT	Constitutive Cyclooxygenase (COX-1) and Inducible Cyclooxygenase (COX-2): Rationale for Selective Inhibition and Progress to Date, Don E. Griswold and Jerry L. Adams, Medicinal Research Reviews, Vol. 16, No. 2, pp. 181-206, (1996).

EXAMINER

DATE CONSIDERED

6/29/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
200.1079US

SERIAL NO.: 09/154,194

10(033,051)

## LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Ronald M. BURCH, et al.

FILING DATE:  
September 17, 1998GROUP: 1614  
1639

10/033055

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES
	BL						

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

BM	Cyclooxygenase in biology and disease, Raymond N. Dubois, et al., FASEB J. Vol. 12 pp. 1063-1073 (1998).
BN	Pharmacology of Meloxicam, A new Non-Steroidal Anti-Inflammatory Drug With An Improved Safety Profile Through Preferential Inhibition of COX-2, G. Engelhardt, British J. Rheumatology, 35 (supp 1):4-12, (1996).
BO	Cyclooxygenase 1 Contributes to Inflammatory Responses in Rats and Mice: Implications for Gastrointestinal Toxicity, John L. Wallace, et al. Gastroenterology, 115:101-109 (1998).
BP	Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications, M. Pairet and G. Engelhardt, Fundam. Clin. Pharmacol. 10:1-15, (1996).
BR	Involvement of Prostaglandins Produced by Cyclooxygenase-1 in Murine Visceromonociception Induced by Phenylquinone, Hidenobu Kusuvara, et al. Prostaglandins 55: 43-49, (1998).
BS	Effect of COX-1 and COX-2 Inhibition on Induction and Maintenance of Carrageenan-Evoked Thermal Hyperalgesia in Rats. D. Dirig, et al. J. Pharmacol. And Experimental Therapeutics Vol285, No. 3, pp 1031-1038.
BT	

EXAMINER

DATE CONSIDERED

6/29/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079US		SERIAL NO.: 09/154,354 10/033,055	
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)				APPLICANT(S): Ronald M. BURCH, et. al.			
				FILING DATE: September 17, 1998		GROUP: 1627 1639	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AE	9 9 0 7 4 1 3	2/18/99	WO			
	AF	9 9 3 2 1 1 9	7/1/99	WO			
	AG						
	AH						
	AI						
	AJ						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AK	Effect of meloxicam on postoperative pain after abdominal hysterectomy, J.P. Thompson et al. <i>British Journal of Anaesthesia</i> 84 (2) 151-4 (2000).					
	AL	Intrathecal cyclooxygenase inhibitor administration attenuates morphine antinociceptive tolerance in rats, C.S. Wong et al., <i>British Journal of Anaesthesia</i> 85 (5) 747-51 (2000).					
	AM	Cyclooxygenase inhibitors increase morphine effects on mesolimbic dopamine neurons, M. Melis, et al. <i>Eur. J. Pharmacology</i> 387 (1) R1-R3 (2000).					
	AN	Synergistic antiallodynic effects of spinal morphine with ketorolac and selective COX1- and COX2-inhibitors in nerve-injured rats, J.M. Lashbrook, et al. <i>Pain</i> 82 (1) 65-72 (1999).					
	AO	Enhancement of opioid inhibition of gaba-ergic synaptic transmission by cyclo-oxygenase inhibitors in rat penaqueductal grey neurones, Vaughn et al. <i>British Journal of Pharmacology</i> 123 (8) 1479-81 (1998).					
	AP						
	AQ						
EXAMINER 				DATE CONSIDERED 6/29/04			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079US		SERIAL NO.: 09/156354 <i>10633, 655</i>							
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)				APPLICANT(S): Ronald M. BURCH, et al.									
				FILING DATE: September 17, 1998		GROUP: 1618 <i>1639</i>							
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<i>[Signature]</i>	AA	5	4	7	4	9	9	5	12/12/95	Ducharme et al.	514	241	01/10/94
	AB	5	6	9	1	3	7	4	11/25/97	Black et al.	514	473	05/18/95
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
EXAMINER <i>[Signature]</i>										DATE CONSIDERED <i>6/29/04</i>			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
200.1079USSERIAL NO.: 09/154,84  
10/033 057

## LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Ronald M. BURCH, et al.

FILING DATE:  
September 17, 1998GROUP: 1614  
1657

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>MM</i>	AA	3	8	0	0	0	4	1	03/26/74	Miller, et al.	424	273	03/02/71
	AB	4	3	2	2	4	2	7	03/30/82	Buyinski, et al.	424	260	04/16/81
	AC	4	3	3	8	3	2	4	06/06/82	Gardocki	424	266	03/17/81
	AD	4	4	0	4	2	1	0	09/13/83	Schmidt	424	260	06/30/82
	AE	4	4	0	7	8	0	4	10/04/83	Schmidt	424	260	06/30/82
	AF	4	4	0	7	8	0	5	10/04/83	Schmidt	424	260	06/30/82
	AG	4	4	6	4	3	7	6	06/07/84	Sunshine, et al.	424	253	10/11/83
	AH	4	4	8	6	4	3	6	12/04/84	Sunshine, et al.	424	253	03/11/83
<i>MM</i>	AI	4	4	8	9	0	8	0	12/18/84	Lomen	424	260	12/06/82

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
<i>MM</i>	AJ	2	0	2	3	3	4	9	02/18/91	Canada	A61K	31/44		
	AK	0	2	7	4	8	4	5	07/20/88	EP (A1)	A61K	31/19		
<i>MM</i>	AL	0	3	8	8	1	2	5	09/19/90	EP (A1)	A61K	31/485		

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>MM</i>	AM	Pharmacokinetics and Drug Input Characteristics for a Diclofenac-Codeine Phosphate Combination Following Oral and Rectal Administration A. Hansen, et al. Arzneim.-Forsch./Drug Res. 46 (I), 57-63 (1996).
<i>MM</i>	AN	Comparison of a Standard Ibuprofen Treatment Regimen with a New Ibuprofen/Paracetamol/Codeine Combination in Chronic Osteo-arthritis G. K. Vlok, et al. Univ. Stellenbosch and Tygerberg Hospital, Dept. Orthopaedic Surg. pp 3-6, (1987).
	AO	
	AP	
	AQ	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant


FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079US		SERIAL NO.: <del>09134,334</del> 101033,055	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)				APPLICANT(S): Ronald M. BURCH, et al.			
				FILING DATE: September 17, 1998		GROUP: <del>1614</del> 1639	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
MA	BA	4 5 6 7 1 8 3	01/28/86	Sunshine, et al.	514	264	12/12/83
	BB	4 5 6 9 9 3 7	02/11/86	Baker, et al.	514	282	02/11/83
	BC	4 5 7 1 4 0 0	02/18/86	Arnold	514	282	12/18/84
	BD	4 5 8 7 2 5 2	05/06/86	Arnold	514	282	12/18/84
	BE	4 6 1 9 9 3 4	12/28/86	Sunshine, et al.	514	277	07/08/85
	BF	4 6 9 0 9 2 7	09/01/87	Voss, et al.	514	282	02/03/86
	BG	4 8 3 9 1 7 6	06/13/89	Pahkhanian, et al.	424	465	12/08/87
	BH	4 8 4 4 9 0 7	07/04/89	Elger, et al.	424	465	08/14/86
	BI	4 9 2 7 8 5 4	05/22/90	Sunshine, et al.	514	570	08/21/89
	BJ	5 1 6 4 3 9 8	12/17/92	Sims, et al.	514	282	04/01/91
MA	BK	5 1 9 0 9 4 7	03/02/93	Riess, et al.	514	282	08/16/91
	BL	5 2 4 0 6 9 4	08/31/93	Gwaltney, Jr.	424	45	12/19/91
<b>FOREIGN PATENT DOCUMENTS</b>							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
MA	BM	0 0 6 8 8 3 8	06/25/82	EP (A1)	A61K	31/485	Z
	BN	0 0 6 8 8 3 8	06/25/82	EP (B1)	A61K	31/485	Z
MA	BO	2 0 8 1 6 0 4	05/01/95	Canada	A61K	031/135	
	BP						
	BQ						
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	BR						
	BS						
	BT						
EXAMINER <i>MA</i>				DATE CONSIDERED 01/29/04			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079US		SERIAL NO.: 09/154,334 101033055									
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)				APPLICANT(S): Ronald M. BURCH, et al.											
				FILING DATE: September 17, 1998		GROUP: 1014 1639									
<b>U.S. PATENT DOCUMENTS</b>															
*EXAMINER INITIAL	DOCUMENT NUMBER	DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
		5	4	0	9	9	4	4							
MA	AA	5	4	0	9	9	4	4	04/25/95	Black, et al.	514	359	03/12/93		
	AB	5	4	3	6	2	6	5	06/25/95	Black, et al.	514	420	11/12/93		
	AC	5	5	1	0	3	6	8	04/23/96	Lau, et al.	514	419	05/22/95		
	AD	5	5	2	1	2	1	3	05/28/96	Prasit, et al.	514	443	08/29/94		
	AE	5	5	5	0	1	4	2	08/27/96	Ducharme et al.	514	365	05/08/95		
	AF	5	5	5	2	4	2	2	09/03/96	Gauthier, et al.	514	368	01/11/95		
	AG	5	6	0	4	2	5	3	02/18/97	Lau, et al.	514	415	05/22/95		
MA	AH	5	6	3	9	7	8	0	06/17/97	Lau, et al.	514	419	05/22/95		
	AI														
<b>FOREIGN PATENT DOCUMENTS</b>															
		DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
		YES	NO												
	AJ														
	AK														
	AL														
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>															
MA	AM	Anti-inflammatory Drugs and Their Mechanism of Action J.R. Vane, et al. Inflamm. Res. 47, Supplement 2 (1998).													
	AN														
	AO														
	AP														
	AQ														
EXAMINER										DATE CONSIDERED					
MA										6/29/94					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant															

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
200.1079US

SERIAL NO.: 09454334

10/033,055



## LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Ronald M. BURCH, et al.

FILING DATE:  
September 17, 1998

GROUP: 1627

1639

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLAS S	TRANSLATION	
													YES	NO
AA	0	6	5	4	2	6	3	05/24/95	EP (A1)	A61K	31/135			
	AB	0	6	5	4	2	6	3	05/24/95	EP (B1)	A61K	31/135		
	AC	9	7	1	7	9	7	8	05/22/97	WO	A61K	33/00		
AD	9	7	2	5	9	8	8	07/24/97	WO	A61K	31/495			
	AE	9	7	3	2	8	5	7	09/12/97	WO	C07D	241/104		

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AF	Dray et al. New Pharmacological Strategies for Pain Relief. <u>Annual Review of Pharmacology &amp; Toxicology</u> , 36, pp. 253-280. (1996).
AG	Brasseur, L. Revue des therapeutiques pharmacologiques actuelles de la douleur. <u>Drugs</u> , 53 Suppl 2, pp. 10-17. (1997)
AH	Rang et al. New molecules in analgesia. <u>British Journal of Anesthesia</u> , 75, pp. 145-156 (1995)
AI	Beaver, WT. Combination Analgesics. <u>American Journal of Medicine</u> , 77 (Suppl 3A), pp. 38-53. (1984).
AJ	Beaver, WT. Chapter 29: Nonsteroidal Antiinflammatory Analgesics and Their Combinations with Opioids. In <u>Evaluation and Treatment of Chronic Pain</u> , 2 <sup>nd</sup> ed., William & Wilkins pp. 363-383. (1992).
AK	Goodman & Gilman's. <u>The Pharmacological Basis of Therapeutics</u> , 9 <sup>th</sup> Edition. McGraw-Hill, New York, pp 535 and 551-552.
AL	Picard et al. Ketorolac potentiates morphine in postoperative patient-controlled analgesia. <u>Pain</u> , 73, 3 pp. 401-406. (1997).
AM	Elches et al. Continuous Intravenous Administration of Ketorolac Reduces Pain and Morphine Consumption After Total Hip or Knee Arthroplasty. <u>Anesthesia &amp; Analgesia</u> , 81 (6), pp. 1175-1180. (1995).
AN	Hodsman et al. The morphine sparing effects of diclofenac sodium following abdominal surgery. <u>Anaesthesia</u> , 42(9), pp. 1005-1008. (1987).
AO	Kaasalainen et al. Developments in the treatment of cancer pain in Finland: The third nation-wide survey. <u>Pain</u> , 70, 2-3, pp. 175-183. (1997).
AP	Sunshine et al. Analgesic Efficacy of a Hydrocodone with Ibuprofen Combination Compared with Ibuprofen Alone for the Treatment of Acute Postoperative Pain. <u>Journal of Clinical Pharmacology</u> , 37 (10), pp. 908-915. (1997).
AQ	Insel. Chapter 27: Analgesic-Antipyretic and Anti-Inflammatory Agents. In Hardman, ed., <u>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics</u> , 9 <sup>th</sup> Edition. McGraw-Hill, New York, pp. 654-655. (1996).
AR	Polisson. Non-steroidal Anti-Inflammatory Drugs: Practical and Theoretical Consideration in Their Selection. <u>The American Journal of Medicine</u> , 100 (Suppl 2A), pp. 2A-31S - 2A-36S. (1996).
AS	Vane, J. Towards a better aspirin. <u>Nature</u> , 367, pp. 215-216. (1994).
AT	Simon, L.S. Nonsteroidal Antiinflammatory Drugs and Their Effects: The Importance of COX 'Selectivity'. <u>Journal of Clinical Rheumatology</u> , 2 (3), pp. 135-140. (1996).

EXAMINER

DATE CONSIDERED


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

DEC 02 2002

TECH CENTER 1600/2900





FORM PTO 49 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 200.1079US	SERIAL NO.: 09/154,354 101 033,055
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT(S): Ronald M. BURCH, et al.	
		FILING DATE: September 17, 1998	GROUP: 1827 1639
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)			
BA	Van Ryn et al. Selective cyclooxygenase-2 inhibitors: pharmacology, clinical effects, and therapeutic potential. <u>Expert Opinion On Investigational Drugs</u> , pp. 609-614. (1997).		
BB	Vane et al. New insights into the mode of action of anti-inflammatory drugs. <u>Inflammation Research</u> , 44, (No.1), pp 1-10 (1995).		
BC	Engelhardt. Meloxicam: A Preferential Inhibitor of COX-2. <u>British Journal of Rheumatology</u> , 34, Abstract Suppl. 1, p. 48. (1995). Abstract.		
BD	Lane, N.E. Pain Management in Osteoarthritis: The Role of COX-2 Inhibitors. <u>Journal of Rheumatology</u> , Vol. 24, Suppl 49, pp. 20-24. (1997).		
BE	Boyce et al. L-745,337: A Selective Inhibitor of Cyclooxygenase-2 Elicits Antinociception But Not Gastric Ulceration in Rats. <u>Neuropharmacology</u> Vol. 33, pp. 1609-1611. (1994).		
BF	Donnelly et al. COX-II Inhibitors - a new generation of safer NSAIDS? <u>Alimentary Pharmacology and Therapeutics</u> , 11, 2, pp. 227-236. (1997).		
BG	Wallace, J.L. Nonsteroidal Anti-inflammatory Drugs and Gastroenteropathy: The Second Hundred Years. <u>Gastroenterology</u> , 112, 3, pp. 1000-1016. (1997).		
BH	Robinson, D.R. Regulation of Prostaglandin Synthesis by Antiinflammatory Drugs. <u>J Rheumatology</u> , 24, Suppl. 47, pp. 32-39. (1997).		
BI	Tannenbaum et al. An Evidence-Based Approach to Prescribing NSAIDS in Musculoskeletal Disease: A Canadian Consensus. <u>Canadian Medical Association Journal</u> , 155, 1, pp. 77-88. (1996).		
BJ	Mehlich et al. Analgesic Efficacy and Plasma Levels of a Highly Selective Inhibitor of COX-2 (SC-58635, SC) in Patients with Postsurgical Dental Pain. <u>Journal of Clinical Pharmacology</u> , 37, 9, 883. (1997). Abstract.		
BK	Dammann. Selective COX-2 Inhibition: Its Relevance for NSAID-Gastrointestinal Toxicity. <u>Gut</u> , 39, Suppl. 3, A151. (1996). Abstract.		
BL	Penning et al. Synthesis and Biological Evaluation of the 1, 5 -diarylpyrazole class of cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). <u>Journal Of Medicinal Chemistry</u> , 40(9), 1347-65. (1997).		
BM	Lipsky et al. Outcome of Specific COX-2 Inhibition in Rheumatoid Arthritis. <u>Journal Of Rheumatology</u> , 24 Suppl 49, pp. 9-14. (1997).		
BN			
BO			
BP			
BQ			
BR			
BS			
BT			
EXAMINER	DATE CONSIDERED 6/29/04		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

RECEIVED  
DEC 02 2002  
TECH CENTER 1600/2900



Sheet 1 of 1

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
200.1079USSERIAL NO.:  
09/154,354 10/033,055

## LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Ronald M. BURCH, et al.

FILING DATE:  
September 17, 1998GROUP:  
1639

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
AM	0 7 3 4 2 7 5	11/04/1997	Australia	C07D	261/08		
AI							
AJ							
AK							
AL							

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AM	
AN	
AO	
AP	
AQ	
AR	
AS	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED  
DEC 8 2 2002  
TECH CENTER 1800/2800